A Single-Dose, Single-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB019, Daclizumab High Yield Process (DAC HYP), in Japanese and Caucasian Adult Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2015
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen Idec
- 01 May 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2014 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov record.
- 28 Feb 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.